Company · Public · DNLI
Denali Therapeutics Inc.
Neurodegeneration company applying its Oligonucleotide Transport Vehicle to cross the blood-brain barrier; DNL628 (OTV:MAPT) is designed to reduce tau through MAPT targeting in Alzheimer's disease.
EvidenceEarly
Listing
Public
Ticker
DNLI
Headquarters
—
Founded
—
Technology
Oligonucleotide Transport Vehicle (OTV), blood-brain barrier delivery
Category
Market cap
Private
Longevity thesis
Brain delivery is the limiting factor for oligonucleotide medicines in age-associated neurodegeneration; a transport vehicle that solves it applies across MAPT and beyond.
Pipeline
| Programme | Stage | Focus |
|---|---|---|
| DNL628 | Phase 1b | Alzheimer's disease |
Recent developments
Scientific evidence
EvidenceEarly
Company-reported only. LONGEFI holds no independent Evidence Record for DNL628 and records no later-stage development.
LONGEFI analysis
Curated as ordinary Company Knowledge: programme identity, target, technology, indication, stage and currentness. No relationship to any other company is encoded.
Analysis is research commentary. It is not investment advice or a recommendation.